Oncotelic Therapeutics
Income Statement

Last updated:

Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. The net income dropped to -$7,903,093 and profit margin reached -11290%. Total operating expenses were $6,718,015.

Profit Margin

Oncotelic Therapeutics, Inc. (OTC:OTLC): Profit margin
2014 95K -12.64M -13312.63%
2015 0 -13.65M
2016 0 -13.65M
2017 -100 -13.81M 13812000%
2018 -100 -2.73M 2737000%
2019 0 -7.38M
2020 1.74M -11.50M -660.65%
2021 0 -11.39M
2022 0 17.81M
2023 70K -7.90M -11290.13%

OTLC Income Statement (2014 โ€“ 2023)

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue
Revenue
70K001.74M0-100-1000095K
Cost of revenue
012.84K61.51K060.60K09K020K0
Gross profit
70K-12.84K-61.51K1.74M-60.60K-100-9.1K0-20K95K
Operating exp.
Research and development
61.14K756.91K3.65M4.30M1.37M815K10.47M8.76M9.08M7.40M
Selling and marketing
0000000000
Total operating expenses
6.71M5.61M9.12M9.32M4.31M3.00M13.84M13.75M13.68M12.65M
Operating income
-6.64M-9.72M-9.12M-7.58M-4.31M-3.00M-13.84M-13.75M-13.68M-12.65M
Other income (expenses), net
-1.55M14.39M-1.39M-2.38M-2.32M249K30K-1K28K3K
Income before tax
-8.20M4.67M-10.51M-9.97M-6.63M-2.73M-13.81M-13.65M-13.65M-12.64M
Income tax expense
0-13.14M876.56K1.52M749.60K-265K-30K-105K-28K-3K
Net income
-7.90M17.81M-11.39M-11.50M-7.38M-2.73M-13.81M-13.65M-13.65M-12.64M
Earnings per share
Basic EPS
-0.010.04-0.03-0.13-0.12-0.07-0.52-0.51-0.54-0.75
Diluted EPS
-0.010.03-0.03-0.13-0.12-0.07-0.52-0.51-0.54-0.75
Data sourceData sourceData sourceData sourceData sourceData sourceData sourceData sourceData source